Metabolic consequences of advanced chronic heart failure and its modification by implantation of a durable left ventricular assist device

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023001%3A_____%2F24%3A00085174" target="_blank" >RIV/00023001:_____/24:00085174 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216208:11110/24:10483477 RIV/00216208:11120/24:43927444

Výsledek na webu

<a href="https://www.imrpress.com/journal/RCM/25/11/10.31083/j.rcm2511388/htm" target="_blank" >https://www.imrpress.com/journal/RCM/25/11/10.31083/j.rcm2511388/htm</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.31083/j.rcm2511388" target="_blank" >10.31083/j.rcm2511388</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Metabolic consequences of advanced chronic heart failure and its modification by implantation of a durable left ventricular assist device

Popis výsledku v původním jazyce

Heart failure (HF) is a clinical syndrome characterized by the inability of the heart to provide adequate perfusion to tissues and organs, resulting in typical symptoms such as fatigue, dyspnea, dyspepsia, or swelling due to decreased cardiac output. With its increasing prevalence, heart failure has become one of the leading causes of morbidity and mortality worldwide, imposing a significant burden on the population by reducing long-term life expectancy and raising hospital costs. Indeed, over 20 million people worldwide suffer from heart failure, with a 5-year mortality rate of 60–70%. As heart failure progresses, various structural and metabolic changes occur within the myocardium and organ systems. In the past two decades, therapeutic options for heart failure patients have significantly expanded. In addition to novel pharmacological treatment, advanced surgical methods such as heart transplantation (HTx) and the implantation of durable left ventricular assist devices (LVADs) are available for patients with end-stage heart failure. This review discusses the pathophysiological aspects and metabolic consequences of heart failure and metabolic changes, as well as the benefits and challenges of implanting a left ventricular assist device. Furthermore, future targets for heart failure diagnostics and therapy will be highlighted.

Název v anglickém jazyce

Metabolic consequences of advanced chronic heart failure and its modification by implantation of a durable left ventricular assist device

Popis výsledku anglicky

Heart failure (HF) is a clinical syndrome characterized by the inability of the heart to provide adequate perfusion to tissues and organs, resulting in typical symptoms such as fatigue, dyspnea, dyspepsia, or swelling due to decreased cardiac output. With its increasing prevalence, heart failure has become one of the leading causes of morbidity and mortality worldwide, imposing a significant burden on the population by reducing long-term life expectancy and raising hospital costs. Indeed, over 20 million people worldwide suffer from heart failure, with a 5-year mortality rate of 60–70%. As heart failure progresses, various structural and metabolic changes occur within the myocardium and organ systems. In the past two decades, therapeutic options for heart failure patients have significantly expanded. In addition to novel pharmacological treatment, advanced surgical methods such as heart transplantation (HTx) and the implantation of durable left ventricular assist devices (LVADs) are available for patients with end-stage heart failure. This review discusses the pathophysiological aspects and metabolic consequences of heart failure and metabolic changes, as well as the benefits and challenges of implanting a left ventricular assist device. Furthermore, future targets for heart failure diagnostics and therapy will be highlighted.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30201 - Cardiac and Cardiovascular systems

Projekt

<a href="/cs/project/LX22NPO5104" target="_blank" >LX22NPO5104: Národní institut pro výzkum metabolických a kardiovaskulárních onemocnění</a><br>

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Rok uplatnění

2024

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Reviews in cardiovascular medicine

ISSN

1530-6550

e-ISSN

2153-8174

Svazek periodika

25

Číslo periodika v rámci svazku

11

Stát vydavatele periodika

CN - Čínská lidová republika

Počet stran výsledku

12

Strana od-do

"art. no. 388"

Kód UT WoS článku

001368590300003

EID výsledku v databázi Scopus

2-s2.0-85210745156